Virtus Health is a fertile offering: RBS Morgans

The world's only pure ARS-listed company is well placed to grow in the near term, according to RBS Morgans.

RBS Morgans initiated coverage on Virtus Health (VRT) with an "outperform" rating as it believes that the fertility services company could run up another 20% over the next 12 months.

The broker set a one-year forward price target of $8.64 for the stock, which is trading at $7.19 at 1235 AEST, and is forecasting a dividend yield 3.3%.

{{content.question}}

SMS Code Sent…

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa

Related Articles